Eisai reports seizure data

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said two of three doses of perampanel ( E2007) as an adjunctive therapy met the primary endpoint vs. placebo in the Phase III Study 306 trial to treat partial seizures in patients with epilepsy. The 4 and 8 mg doses significantly reduced median seizure frequency per 28 days in the maintenance period in the double-blind, dose-escalation, international trial in 706 patients. The 2 mg dose missed the endpoint. ...